Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Signatera Assessment in Early-Stage Endometrial Cancer

Not-yet-recruiting interventional trial SIGNAL-EMC 101 (Natera sponsor): after surgery, high-intermediate-risk stage I endometrial-cancer patients are stratified by postoperative Signatera Genome ctDNA; ctDNA-negative patients are randomized 1:1 to ctDNA-guided observation versus adjuvant vaginal brachytherapy, with a 3-year RFS non-inferiority primary endpoint. Planned enrollment 1,010. ClinicalTrials.gov API v2 on 13 Nov 2026: NOT_YET_RECRUITING, start October 2026, primary completion October 2034, last update 2026-06-17, phase N/A.

Natera, Inc.